论文部分内容阅读
目的探讨埃克替尼联合培美曲塞治疗埃克替尼获得性耐药的非小细胞肺癌患者的近期疗效及安全性。方法 48例患者按2∶1比例随机分成观察组与对照组,对照组单独给予培美曲塞为基础的化疗,观察组在对照组的基础口服埃克替尼。结果观察组客观反映率(CR+PR)为31.2%,有效率(CR+PR+SD)为71.9%,而对照组客观反映率为18.8%,有效率为43.8%,两组比较差异非常显著(P<0.01)。两组患者除皮疹的发生率有统计学差异外,其余不良反应均无统计学差异。结论埃克替尼联合培美曲塞治疗埃克替尼继发性耐药的非小细胞肺癌患者的近期疗效优于单纯培美曲塞化疗,不良反应在可耐受范围。
Objective To investigate the short-term efficacy and safety of icotinib combined with pemetrexed in the treatment of patients with acquired resistance to imatinib. Methods Forty-eight patients were randomly divided into observation group and control group according to the ratio of 2: 1. The control group was given pemetrexed-based chemotherapy alone. The observation group was given ictenil on the basis of the control group. Results The objective response rate (CR + PR) of the observation group was 31.2%, the effective rate (CR + PR + SD) was 71.9%, while the control group objective response rate was 18.8%, the effective rate was 43.8%, the difference was significant (P <0.01). In addition to the incidence of rash in both groups were statistically different, the remaining adverse reactions were not statistically different. Conclusions Icitinib combined with pemetrexed is superior to mepereteme alone in the treatment of patients with Icophistinib secondary refractory non-small cell lung cancer, with adverse reactions in the tolerable range.